Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | CTSB | P07858 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5728848 | 0.88 | TDP1 (0.75) | TDP1CTSBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL7788656 | 0.87 | TDP1 (0.80) | TDP1CTSBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL17553044 | 0.81 | TDP1 (0.53) | TDP1CTSBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL31727 | 0.81 | HSD17B10 (0.55) | TDP1SMN1; SMN2MEN1KMT2AHSD17B10 | |
| SCHEMBL28307480 | 0.80 | TDP1 (0.57) | TDP1CTSBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5052440 | 0.80 | HPRT1 (0.65) | TDP1CTSBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL1561998 | 0.79 | TSHR (0.60) | TDP1CTSBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5252374 | 0.79 | TDP1 (0.61) | TDP1CTSBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL10531193 | 0.77 | TSHR (0.65) | TDP1SMN1; SMN2MEN1KMT2AHSD17B10 | |
| SCHEMBL5255439 | 0.77 | TSHR (0.65) | TDP1CTSBSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043967-A1 | PREPARATION METHOD FOR AND USE OF NANOPOROUS CARBON MATERIAL HAVING CONTINUOUS STRUCTURE | 东南大学 | 2025-03-06 | — | — | WO | claimed |
| CN-118515261-A | Preparation method of nano porous carbon material with continuous structure and application of nano porous carbon material as heat insulation material | 东南大学 | 2024-08-20 | — | — | CN | claimed |
| CN-117088357-A | Preparation method and application of nano porous carbon material with continuous structure | 东南大学 | 2023-11-21 | — | — | CN | claimed |
| CN-110231206-A | The pre-treating method of persistence organic pollutant in a kind of quick measurement Atmospheric particulates | 北京化工大学 | 2019-09-13 | — | — | CN | claimed |
| EP-2094272-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2009-09-02 | — | — | EP | claimed |
| WO-2008036843-A2 | NITROGEN CONTAINING SUBSTITUTED HETEROCYCLES AS PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| CN-118515261-A | Preparation method of nano porous carbon material with continuous structure and application of nano porous carbon material as heat insulation material | 东南大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-117088357-A | Preparation method and application of nano porous carbon material with continuous structure | 东南大学 | 2023-11-21 | — | — | CN | disclosed |
| US-11773057-B2 | Naphthalenesulfonamide compound, preparation method, and application | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11396496-B2 | 1,4-substituted isoquinoline inhibitors of KEAP1/NRF2 protein-protein interaction | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-07-26 | — | — | US | disclosed |
| CN-112367983-A | 1,4 substituted isoquinoline inhibitors of KEAP1/NRF2 protein-protein interaction | 伊利诺伊大学评议会 | 2021-02-12 | — | — | CN | disclosed |
| US-20210017135-A1 | 1,4-SUBSTITUTED ISOQUINOLINE INHIBITORS OF KEAP1/NRF2 PROTEIN-PROTEIN INTERACTION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2021-01-21 | — | — | US | disclosed |
| US-20210017135-A1 | 1,4-SUBSTITUTED ISOQUINOLINE INHIBITORS OF KEAP1/NRF2 PROTEIN-PROTEIN INTERACTION | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2021-01-21 | — | — | US | disclosed |
| WO-1994012163-A1 | 2-NITROARYL AND 2-CYANOARYL COMPOUNDS AS REGULATORS OF NITRIC OXIDE SYNTHASE | ABBOTT LABORATORIES (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5138098-A | Catalytic actlation using complexing agent | AMOCO CORPORATION (US) | 1992-08-11 | — | — | US | disclosed |
| US-4482438-A | ELECTROLYSIS ANODIC OXIDATION, REDOX SYSTEMS/ ELECTROLYSIS, ANODIC OXIDATION, REDOX SYSTEMS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-11-13 | — | — | US | disclosed |
| EP-0102762-A2 | Method of performing a chemical reaction | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-03-14 | — | — | EP | disclosed |
| EP-0023584-B1 | PROCESS FOR THE PREPARATION OF TRIFLUOROMETHYL NAPHTHALENES | BAYER AG (DE) | 1983-01-26 | — | — | EP | disclosed |
| US-4331613-A | Process for the preparation of trifluoromethylnaphthalenes | BAYER AKTIENGESELLSCHAFT (DE) | 1982-05-25 | — | — | US | disclosed |
| EP-0023584-A1 | Process for the preparation of trifluoromethyl naphthalenes | BAYER AG (DE) | 1981-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773057-B2 | Naphthalenesulfonamide compound, preparation method, and application | NFE2L2, KEAP1, NFE2 | TDP1 4816/4885CTSB 462/4885SMN1; SMN2 4116/4885 |
| US-11396496-B2 | 1,4-substituted isoquinoline inhibitors of KEAP1/NRF2 protein-protein interaction | KEAP1, NFE2L2, NFE2 | TDP1 3589/4885CTSB 4289/4885SMN1; SMN2 1670/4885 |
| US-20210017135-A1 | 1,4-SUBSTITUTED ISOQUINOLINE INHIBITORS OF KEAP1/NRF2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, NFE2 | TDP1 3589/4885CTSB 4289/4885SMN1; SMN2 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.